Evidence map›Paper›PMID 39920531›Full record

ArticleTherapeutic innovation & regulatory science2025

Assessment of Local Pharmaceutical Manufacturing Sector in a Low-income Country: A Descriptive Study.

Tesfa Marew, Anteneh Belete, Frances J Richmond, Tsige Gebre-Mariam

Abstract read
PubMed Publisher
In one paragraph

Article in Therapeutic innovation & regulatory science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tesfa MarewDepartment of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, P.O. Box: 1176 , Addis Ababa, Ethiopia.
Anteneh BeleteDepartment of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, P.O. Box: 1176 , Addis Ababa, Ethiopia.
Frances J RichmondDepartment of Regulatory and Quality Sciences, School of Pharmacy, University of Southern California, LA, USA.
Tsige Gebre-MariamDepartment of Pharmaceutics and Social Pharmacy, School of Pharmacy, College of Health Science, Addis Ababa University, P.O. Box: 1176 , Addis Ababa, Ethiopia. tsige.gmariam@aau.edu.et.ORCID http://orcid.org/0000-0001-7619-2270

Funding

Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia. CHS/RTTD/131/2018
6 · The paper itself

Abstract

backgroundIn high-income countries and emerging economies, pharmaceutical manufacturing is a driver for socioeconomic development. In sub-Saharan Africa, local pharmaceutical production is still fledgling largely because of historical economic and technological asymmetry. In Ethiopia alike, this environment has changed little despite six decades long operations and several support initiatives; access to essential medicines remained a persistent challenge. Despite a few fragmented reports on trends and profiles of the sector, in-depth investigations into underlying challenges remain limited. This study explores the perspectives and insights of upfront executives and technical personnel in the Ethiopian pharmaceutical industry on its current state, challenges and opportunities for enhancing local production capacity. The findings are triangulated with literature reports and provide valuable insights for developing intervention strategies and policy updates.

methodsA validated structured survey questionnaire was disseminated to professionals working in local pharmaceutical companies. Multiple regression analysis was conducted to study the effects of different factors on the performance of the local manufacturing sector.

resultsOver half of the professionals (55.1%) rated the current production technology as advanced while 68% described it as semi-automated. Close to one-third (31.6%) reported that the companies are operating at acceptable level of performance, and 51.5% reported low-capacity utilization in their companies. Most professionals (67.8%) viewed export market activities as poor and many identified weak research and development activities. Unplanned operations downtimes, limited physical infrastructure, inadequate access to foreign currency, shortage and highstaff turnover of qualified experts, lack of commitment from top management, absence of merit-based support system and limitations in compliance with regulatory and quality requirements were reported as major challenges. Multiple linear regression analysis demonstrated that capacity utilization (α = 0.008), research and development capacity (α = 0.014) and export market activities (α = 0.027) have significant impact on the sector performance.

conclusionDespite commendable efforts by the industry and government, limitations in financing, infrastructure, qualified workforce, and quality system implementation are affecting capacity utilization and performance. Absence of reliable staff attraction and retention system, lack of effective leadership and non-favourable working environment were identified as missing elements. Enhancing economies of scale and capacity utilization, addressing policy and infrastructure bottlenecks, providing merit-based support for R&D and quality management, and implementing staff attraction and retention strategies are key steps towards developing competent local pharmaceutical manufacturing sector.

Indexed as

Drug IndustryDeveloping CountriesEthiopiaHumansSurveys and QuestionnairesAccess to essential medicinesCapacity utilizationLocal pharmaceutical manufacturingLow-income countryRegulatory and quality requirementsUnplanned operations downtime

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.